
INCREASED FREQUENCY OF MEFV GENES IN
PATIENTS WITH EPIGASTRIC PAIN SYNDROME Coskun BD1, Kiraz A2, Sevinc E1, Baspinar O3, Cakmak E4 *Corresponding Author: Banu D. Coskun, M.D., Kicikapı Mahallesi Hoca Ahmet Yesevi Cad Hidayet Eraslan sitesi B Blok
No: 12, Talas/Kayseri Turkey. Tel: +90-506-323-24-86. Fax: +90-352-437-52-73. E-mail: demetcoskun2@gmail.com page: 51 download article in pdf format
|
Abstract
Atypical clinical forms of familial Mediterranean fever
(FMF) can be misdiagnosed as therapy-resistant epigastric
pain syndrome (EPS) for they share many of the
same clinical features, such as abdominal pain. Thus, we
aimed to determined the frequency of FMF in patients who
were followed with a diagnosis of therapy-resistant EPS.
Seventy-five patients with therapy-resistant EPS and 20
controls were involved in the study. To detect the FMF in
patients with therapy-resistant EPS, Tel-Hashomer criteria,
family history of FMF were researched and recorded. We
performed performed MEFV gene analysis on all patients.
Forty-three patients with EPS (57.3%) had MEFV gene mutations
and the carrier rate was 30.0%. The most common
MEFV gene alteration was R202Q (55.8%), followed by
E148Q (16.2%), R761H (16.2%), V726A (9.3%), M680I
(9.3%) and M694V (4.6%). Rarely seen mutations in the
Turkish population were also identified: K695R (2.3%),
L110P (2.3%) and G304R (2.3%). Eight patients with EPS
were diagnosed with FMF and started on colchicine therapy.
Three patients with compound heterozygosities for three
mutations, two patients with compound het-erozygosities
for two mutations (K695R/ V726A and R202Q/ R761H),
one patient with homozygous R202Q, one patient with
heterozygous R202Q mutation and one patient with non-
R202Q heterozygous mutation (G304R/–) had clinical FMF
symptoms and were started on colchicine therapy. Patients
who have therapy-resistant EPS should also be questioned
about FMF, especially in high risk populations.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|